ClinicalTrials.gg
RecruitingNCT05064709AIM HIGHerUpdated Oct 23, 2026

Assessment of CCM in HF With Higher Ejection Fraction

An interventional study of Cardiac Contractility Modulation Therapy via OPTIMIZER™ Smart Mini System and OPTIMIZER™ Smart Mini System in Heart Failure, Heart Failure With Preserved Ejection Fraction and Heart Failure With Mid Range Ejection Fraction, sponsored by Impulse Dynamics. Recruiting at 67 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-23.

Primary conditionHeart Failure, DiastolicRegistry: Heart FailureReclassifiedWhy we changed it
Registry
Heart Failure — the first condition term the registry derived for this study.
ClinicalTrials.gg
Heart Failure, Diastolic
Why
  1. The study's listed conditions name Heart Failure, Diastolic, a narrower term within Heart Failure.
Confidence
High: the new condition is named in the study's own listed conditions. Of 351 hand-checked studies reclassified this way, 68% were exactly right and 84% in the right disease family; the registry's first term was right for 5% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by Impulse Dynamics · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Feb 2022; still recruiting 4 years 9 months later.
Updated Oct 23, 2026Eligibility revised2 sites added+1 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
1,500
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 95 studies in Heart Failure, Diastolic with a site in United States — 18 open to participants now, 20 under way, none of them phase 3. Heart Failure, Diastolic · United States.

Planned enrollment
5th of 81
1,500 · median 36
Started
2022
with 4 others
No phase
40 of 95
6 open now
Primary completion
2029-02
later than 13 of 19 live
Registered
70th of 95
by date

Among the 95 studies in Heart Failure, Diastolic with a site in United States, this one is the 5th largest by planned enrollment of the 81 interventional ones that give a count, is one of 5 that started in 2022, is one of 40 with no phase, reaches primary completion later than 13 of the 19 other live ones, and was the 70th registered.

Heart Failure, Diastolic

199 studies on the registry are indexed under Heart Failure, Diastolic; 44 are open to participants now.

Browse Heart Failure, Diastolic studies →

Open to participants now

18 of the 95 studies in Heart Failure, Diastolic with a site in United States are open now. Recruiting first, the newest first:

12 more — sign in →

All 18 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 29 Heart Failure, Diastolic studies recruiting now, 21 (72%) set no upper age limit and 4 (14%) stop at 75 or younger; 3 take children under 18; 6 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 95 studies in Heart Failure, Diastolic with a site in United States, or all of them as a file.
02

Study summary

The AIM HIGHer Clinical Trial will evaluate the safety and efficacy of Cardiac Contractility Modulation (CCM) therapy in patients with heart failure with LVEF ≥40% and ≤70%.

Read the detailed description

The AIM HIGHer Clinical Trial is a prospective, multi-center, randomized, quadruple-blind, sham-controlled, two-part embedded trial of the safety and efficacy of CCM therapy delivered via the OPTIMIZER Smart Mini System in subjects with heart failure and an LVEF ≥40% and ≤70%. Subjects will be enrolled at approximately 150 sites in the US and 75 sites OUS.

All subjects will undergo screening and baseline testing; all eligible subjects will be implanted with the Optimizer System. Subjects will be randomized in a 2:1 ratio to either CCM ON (CCM group) or to CCM OFF (Sham group). The trial will be blinded to the treatment assignment of the device for 18-months. Subjects in the Sham group will have CCM turned ON after completion of the 18-month study visit. Subjects enrolled during Part I (450 subjects) of the trial will continue follow-up through the end of Part II (up to an additional 1,050) and contribute data to both parts of the trial. Each part of the trial is distinguished by a separate scientific purpose. The specific purpose of each part is:

Part I - Establish safety and effectiveness based on functional capacity and health status.

Part II - Establish safety and effectiveness based on clinical outcome data.

03

Conditions studied

  • Heart Failure
  • Heart Failure With Preserved Ejection Fraction
  • Heart Failure With Mid Range Ejection Fraction
  • Heart Failure With Moderately Reduced Ejection Fraction
  • Diastolic Heart Failure

Browse trials for

Keywords

  • HFpEF
  • Heart failure
  • CCM
  • CCM therapy
  • cardiac contractility modulation
  • symptomatic heart failure
  • left ventricular ejection fraction
  • LVEF
  • Optimizer
  • Optimizer Smart Mini
  • Quality of Life
04

In context

Heart Failure, Diastolic Reclassified

199 studies on the registry are indexed under Heart Failure, Diastolic; 44 are open to participants now.

This study's planned enrollment of 1,500 is above the median of 48 across 139 interventional studies indexed under Heart Failure, Diastolic.

Browse Heart Failure, Diastolic studies →

Lead sponsor

Impulse Dynamics is the lead sponsor of 13 studies on the registry; 5 are open to participants now.

Compared within Heart Failure, Diastolic, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Heart Failure. The counts are of registry records indexed under each term, refreshed daily. How we classify →

05

Who can participate

The criteria were revised on the registry on Oct 23, 2026. See what changed

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Signed and dated form;
  2. Male or non-pregnant female, 18 years or older;
  3. Diagnosed with symptomatic heart failure;
  4. ≥40 and ≤70% (as assessed by site echo). A historical echo within 60 days of consent may be used for baseline. Ultrafiltration should not be performed within 30 days of echo;
  5. Subjects must meet at least one of the four following criteria:

    I. Heart failure admission (primary or secondary) within 12 months prior to study consent OR heart failure visit requiring IV therapy OR treated with outpatient Furoscix OR intensification of oral diuresis within 6 months prior to study consent II. PCWP > 15 mmHg up to 6 months prior to consent or within 30 days following consent III. IPAP reading of mean pressure ≥ 22 mmHg in 2 or more readings within 30 days of consent, or 3 or more readings within 60 days across different days, with a sensor implanted ≥ 3 months before first reading

    IV. Natriuretic peptide value (NTproBNP or BNP) should meet or exceed the value below, depending on the presenting rhythm:

    • Normal Sinus Rhythm (NSR): NTproBNP (pg/ml) ≥ 150 or BNP (pg/ml) ≥ 50
    • Atrial Tachyarrhythmia (AT): NTproBNP (pg/ml) ≥ 450 or BNP (pg/ml) ≥ 150
    • Historical natriuretic peptide values within 6 months of consent may be used if subject is in NSR. Subjects in AT on baseline must have natriuretic peptide values collected post-consent.
  6. Subjects must meet one of the following conditions:

    • Have stable, scheduled oral loop diuretic treatment (not just PRN) for a minimum of 30 days before providing study consent unless there is a documented allergy or intolerance. Spironolactone used as a diuretic for patients who cannot tolerate oral loop diuretic is an acceptable alternative.
    • Eligibility for enrollment is maintained for patients on an SGLT2 inhibitor without prescribed concurrent standing loop diuretic therapy if investigators provide instructions for a flexible PRN diuretic regimen (deemed appropriate by the clinician in response to symptoms or weight gain) Note: Stable is defined as no more than a 100% increase or 50% decrease in dose within the last 30 days. A one-time hold of diuretic dosing for 24 hours during the 30-day period is allowed and not an exclusionary event.

Exclusion criteria

Exclusion Criteria:

  1. Resting ventricular rate \<50 or >110 bpm;
  2. Resting systolic blood pressure \<100 or ≥160 mmHg;
  3. greater than 46
  4. Any severe valvular stenotic disease or any severe valvular regurgitation;
  5. Mechanical tricuspid valve;
  6. Complex congenital heart disease;
  7. Diagnosis of any of the following conditions that, in the opinion of the investigator, contributes significantly to the primary symptoms of exercise intolerance: angina, significant pulmonary disease, or currently requires 24-hour home oxygen use or scheduled oral , peripheral vascular disease, orthopedic or rheumatologic conditions;
  8. Unable to walk at least 100 meters or walks more than 450 meters during a 6MWT;
  9. A KCCQ CCS score higher than 85;
  10. Infiltrative/restrictive (e.g., amyloidosis, sarcoidosis, hemochromatosis, Fabry, or radiation-induced heart disease), eccentric LV hypertrophy or inflammatory cardiomyopathy as documented in the medical record;
  11. Unstable angina pectoris within 30 days prior to study consent;
  12. Receiving cardiac resynchronization therapy (CRT); NOTE: Subjects with active/ongoing cardiac resynchronization therapy (CRT) implanted more than one year ago are eligible for inclusion if they are currently classified as class III or higher.
  13. Scheduled for a cardiac surgery or a percutaneous cardiac intervention (PCI) or have undergone cardiac surgery within 90 days or a PCI procedure within 30 days prior to study consent;
  14. Myocardial infarction within 90 days prior to study consent;
  15. Prior heart transplant or ventricular assist device;
  16. Planning to become pregnant during the study;
  17. Dialysis (permanent) or \<15 ml/min/1.73m2;
  18. Participating in another drug or device study that may interfere with the interpretation of study data;
  19. Currently undergoing active chemotherapeutic and/or radiation treatment for cancer or has a history of chemotherapy during the 2-year period prior to study consent;
  20. Expected lifespan of less than 18 months from time of study consent;
  21. Unable to follow through study protocol for any reasons (social support, incarceration, mental illness etc.) in the investigator's judgement.
  22. Insurance denial (after all attempts and appeals have been exhausted, and prior-authorization services utilized, if applicable)
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

06

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
1,500 participants (estimated)

Study arms

  • Experimental
    CCM Group (CCM ON)

    CCM therapy will be turned on in 2/3 of the subjects for the entire duration of the study.

    Device: Cardiac Contractility Modulation Therapy via OPTIMIZER™ Smart Mini System

  • Sham comparator
    Sham Group (CCM OFF)

    CCM therapy will be turned off in 1/3 of the subjects for the first 18 months of the study. After 18 months, CCM therapy will be turned on for the rest of the study duration.

    Device: OPTIMIZER™ Smart Mini System

Interventions

  • DeviceCardiac Contractility Modulation Therapy via OPTIMIZER™ Smart Mini System

    The OPTIMIZER™ Smart Mini System will be implanted and CCM will be programmed ON for the first 18 months (blinded phase). CCM therapy will be programmed to deliver 7 one-hour phases of CCM therapy that are distributed equally over every 24-hour period. CCM will remain on following completion of the 18-month visit.

    Also known as: CCM Group (CCM ON)

  • DeviceOPTIMIZER™ Smart Mini System

    The OPTIMIZER™ Smart Mini System will be implanted and CCM will be programmed OFF for the first 18 months (blinded phase). CCM will be turned on following completion of the 18-month visit.

    Also known as: Sham Group (CCM OFF)

07

What researchers measure

Primary outcomes

  1. Part 1 Efficacy Endpoint - Change in 6-minute walk distance (6MWD) from baseline to 6 months.

    Demonstrate that CCM therapy improves functional capacity in subjects with symptomatic heart failure with LVEF ≥40% and ≤70%. Compare the changes in functional capacity, as measured by the 6-minute walk distance (6MWD), from baseline to 6-months following the randomization date between the two study groups.

    Time frame: 6 months

  2. Part 1 Efficacy Endpoint - Change in the health status from baseline to 6 months as assessed by the Kansas City Cardiomyopathy Questionnaire Clinical Summary Score (KCCQ CSS).

    Demonstrate that CCM therapy improves health status in subjects with symptomatic heart failure with LVEF ≥40% and ≤60%. Compare the changes in health status, as measured by the KCCQ CSS, from baseline to 6-months following the randomization date between the two study groups.

    Time frame: 6 months

  3. Part 1 Safety Endpoint - The incidence of Optimizer device- or procedure-related complications within the first 12 months after implant

    Compare the composite incidence of Optimizer device-related and procedure-related SAEs (complications) for available data collected from implant to 12 months after the Optimizer implantation procedure to a performance goal of 75% free of complications.

    Time frame: 12 months

  4. Part 2 Endpoint - The hierarchical composite of mortality, morbidity, and health status outcomes (KCCQ CSS).

    Demonstrate that CCM therapy improves a composite endpoint of cardiovascular mortality at 18-months, heart failure hospitalizations at 18-months, urgent heart failure visits requiring IV diuretics at 18-months and the Kansas City Cardiomyopathy Questionnaire Clinical Summary Score (KCCQ CSS) at 12-months. Comparison of a hierarchical composite endpoint between the two study groups will be based on the Finkelstein-Schoenfeld global rank method.

    Time frame: 18 months

08

Study locations

65 of 67 sites recruiting
09

References and documents

Publications

  • Abraham WT, Kuck KH, Goldsmith RL, Lindenfeld J, Reddy VY, Carson PE, Mann DL, Saville B, Parise H, Chan R, Wiegn P, Hastings JL, Kaplan AJ, Edelmann F, Luthje L, Kahwash R, Tomassoni GF, Gutterman DD, Stagg A, Burkhoff D, Hasenfuss G. A Randomized Controlled Trial to Evaluate the Safety and Efficacy of Cardiac Contractility Modulation. JACC Heart Fail. 2018 Oct;6(10):874-883. doi: 10.1016/j.jchf.2018.04.010. Epub 2018 May 10. PubMed 29754812 ↗
  • Wiegn P, Chan R, Jost C, Saville BR, Parise H, Prutchi D, Carson PE, Stagg A, Goldsmith RL, Burkhoff D. Safety, Performance, and Efficacy of Cardiac Contractility Modulation Delivered by the 2-Lead Optimizer Smart System: The FIX-HF-5C2 Study. Circ Heart Fail. 2020 Apr;13(4):e006512. doi: 10.1161/CIRCHEARTFAILURE.119.006512. Epub 2020 Apr 8. PubMed 32264716 ↗
  • Tschope C, Butler J, Farmakis D, Morley D, Rao I, Filippatos G. Clinical effects of cardiac contractility modulation in heart failure with mildly reduced systolic function. ESC Heart Fail. 2020 Dec;7(6):3531-3535. doi: 10.1002/ehf2.13126. Epub 2020 Dec 3. PubMed 33274601 ↗
  • Tschope C, Van Linthout S, Spillmann F, Klein O, Biewener S, Remppis A, Gutterman D, Linke WA, Pieske B, Hamdani N, Roser M. Cardiac contractility modulation signals improve exercise intolerance and maladaptive regulation of cardiac key proteins for systolic and diastolic function in HFpEF. Int J Cardiol. 2016 Jan 15;203:1061-6. doi: 10.1016/j.ijcard.2015.10.208. Epub 2015 Oct 27. No abstract available. PubMed 26638055 ↗
  • Aneeq A, Jan M, Nisar S, Zahid S, Kumari U. Cardiac contractility modulation: A new horizon in the management of heart failure with preserved ejection fraction (HFpEF). Cardiovasc Revasc Med. 2024 Apr;61:110. doi: 10.1016/j.carrev.2023.11.007. Epub 2023 Nov 11. PubMed 37980262 ↗

Individual participant data

Plan to share: No

10

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Feb 2022 (actual). Primary completion is estimated for Feb 2029, 83 months after the start.

Of 45 interventional studies with no phase under Heart Failure, Diastolic, half reached primary completion within 48 months of starting (the median), counting those still running; a quarter within 26 and three quarters within 62. This study's planned 83 months is above that.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 21, 2021
First posted
Oct 1, 2021
StartActual
Feb 3, 2022
Primary completionEst.
Feb 1, 2029
CompletionEst.
Feb 1, 2029
Last update
Oct 23, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
2 sites added, 40 sites removed
Show 2 added (2 United States)
  • Clinical One Research · Orlando, United States
  • Northeast Georgia Health System · Gainesville, United States
Show 40 removed
  • Chan Heart Rhythm Institute · Mesa, United States
  • Arizona Heart Rhythm · Phoenix, United States
  • Cardiovascular Consultants, Ltd · Phoenix, United States
  • John Muir Health · Concord, United States
  • University of California Davis Health · Sacramento, United States
  • University of California, San Francisco · San Francisco, United States
  • HCA Florida JFK Hospital · Atlantis, United States
  • Broward Health · Fort Lauderdale, United States
  • Memorial Healthcare System · Hollywood, United States
  • NCA Research Institute - Florida · Naples, United States
  • Revival Clinical Research · Orlando, United States
  • Tallahassee Research Institute · Tallahassee, United States
  • Piedmont Healthcare · Atlanta, United States
  • Franciscan Health Indianapolis · Indianapolis, United States
  • Kansas City Cardiac Arrhythmia Research LLC · Overland Park, United States
  • Ochsner Clinic Foundation · New Orleans, United States
  • North Mississippi Medical Center · Tupelo, United States
  • St. Louis Heart and Vascular · Bridgeton, United States
  • St. Luke&#39;s Hospital · Chesterfield, United States
  • University of Nebraska Medical Center · Omaha, United States
  • Hackensack University Medical Center · Edison, United States
  • Jersey Shore University Medical Center · Edison, United States
  • Weill Cornell Medicine · New York, United States
  • Nuvance Health - Vassar brothers Medical Center · Poughkeepsie, United States
  • Sanger Heart and Vascular · Charlotte, United States
  • TriHealth Bethesda · Cincinnati, United States
  • University Hospitals Cleveland Medical Center · Cleveland, United States
  • Mercy Health- St. Vincent Medical Center LLC · Toledo, United States
  • UPMC Pinnacle Harrisburg · Harrisburg, United States
  • Lancaster General Hospital · Lancaster, United States
  • …and 10 more on the registry record
Oct 23, 2026
Eligibility
2 inclusion criteria edited, 6 added, 1 removed; 3 exclusion criteria edited, 1 added, 1 removed
What changed in the criteria
Inclusion criteria
  • EditedLVEF ≥40 and ≤70% (as assessed by site echo). A historical echo within 60 days of consent may be used for baseline. Ultrafiltration should not be performed within 30 days of echo;
  • RemovedA. Heart failure hospitalization within 12 months prior to study consent OR an urgent heart failure visit requiring IV therapy within 6 months prior to study consent OR B. If there is no heart failure hospitalization within 12 months prior to study consent OR an urgent heart failure visit requiring IV therapy within 6 months prior to study consent, an elevated BMI-adjusted natriuretic peptide value must be achieved (Refer to Table 1 in Section 9.2.6)
  • AddedSubjects must meet at least one of the four following criteria:
  • AddedHeart failure admission (primary or secondary) within 12 months prior to study consent OR heart failure visit requiring IV therapy OR treated with outpatient Furoscix OR intensification of oral diuresis within 6 months prior to study consent II. PCWP > 15 mmHg up to 6 months prior to consent or within 30 days following consent III. IPAP reading of mean pressure ≥ 22 mmHg in 2 or more readings within 30 days of consent, or 3 or more readings within 60 days across different days, with a sensor implanted ≥ 3 months before first reading
  • AddedNatriuretic peptide value (NTproBNP or BNP) should meet or exceed the value below, depending on the presenting rhythm:
  • AddedNormal Sinus Rhythm (NSR): NTproBNP (pg/ml) ≥ 150 or BNP (pg/ml) ≥ 50
  • AddedAtrial Tachyarrhythmia (AT): NTproBNP (pg/ml) ≥ 450 or BNP (pg/ml) ≥ 150
  • AddedHistorical natriuretic peptide values within 6 months of consent may be used if subject is in NSR. Subjects in AT on baseline ECG must have natriuretic peptide values collected post-consent.
  • EditedHave stable, scheduled oral loop diuretic treatment (not just PRN) for a minimum of 30 days before providing study consent unless there is a documented allergy or intolerance. Spironolactone used as a diuretic for patients who cannot tolerate oral loop diuretic is an acceptable alternative.
Exclusion criteria
  • ChangedBefore Exercise tolerance limited by a condition other than heart failure that, in the opinion of the investigator, contributes significantly to the primary symptoms of shortness of breath and/or exercise intolerance;Now Diagnosis of any of the following conditions that, in the opinion of the investigator, contributes significantly to the primary symptoms of exercise intolerance: angina, significant pulmonary disease, or currently requires 24-hour home oxygen use or scheduled oral steroids, peripheral vascular disease, orthopedic or rheumatologic conditions;
  • ChangedBefore Hypertrophic, infiltrative/restrictive or inflammatory cardiomyopathy;Now Infiltrative/restrictive (e.g., amyloidosis, sarcoidosis, hemochromatosis, Fabry, or radiation-induced heart disease), eccentric LV hypertrophy or inflammatory cardiomyopathy as documented in the medical record;
  • RemovedAcute, decompensated heart failure requiring IV therapy or ultrafiltration within 30 days prior to consent, in the hospital or an outpatient setting;
  • EditedUnable to follow through study protocol for any reasons (social support, incarceration, mental illness etc.) in the investigator's judgement.
  • AddedInsurance denial (after all attempts and appeals have been exhausted, and prior-authorization services utilized, if applicable)
Oct 23, 2026
Site contacts
Changed at 2 sites. See the sites
Show 2 sites
  • St. Francis Hospital - Tulsa · Tulsa, United StatesContact •••8500→•••1606Contact m•••@saintfrancis.com→r•••@saintfrancis.com
  • Bon Secours St. Mary's · Richmond, United StatesContact person changed (no phone or email listed)
Oct 23, 2026
Show all 1 update
  1. Oct 23, 2026
    2 sites added, 40 sites removed
    Show 2 added (2 United States)
    • Clinical One Research · Orlando, United States
    • Northeast Georgia Health System · Gainesville, United States
    Show 40 removed
    • Chan Heart Rhythm Institute · Mesa, United States
    • Arizona Heart Rhythm · Phoenix, United States
    • Cardiovascular Consultants, Ltd · Phoenix, United States
    • John Muir Health · Concord, United States
    • University of California Davis Health · Sacramento, United States
    • University of California, San Francisco · San Francisco, United States
    • HCA Florida JFK Hospital · Atlantis, United States
    • Broward Health · Fort Lauderdale, United States
    • Memorial Healthcare System · Hollywood, United States
    • NCA Research Institute - Florida · Naples, United States
    • Revival Clinical Research · Orlando, United States
    • Tallahassee Research Institute · Tallahassee, United States
    • Piedmont Healthcare · Atlanta, United States
    • Franciscan Health Indianapolis · Indianapolis, United States
    • Kansas City Cardiac Arrhythmia Research LLC · Overland Park, United States
    • Ochsner Clinic Foundation · New Orleans, United States
    • North Mississippi Medical Center · Tupelo, United States
    • St. Louis Heart and Vascular · Bridgeton, United States
    • St. Luke&#39;s Hospital · Chesterfield, United States
    • University of Nebraska Medical Center · Omaha, United States
    • Hackensack University Medical Center · Edison, United States
    • Jersey Shore University Medical Center · Edison, United States
    • Weill Cornell Medicine · New York, United States
    • Nuvance Health - Vassar brothers Medical Center · Poughkeepsie, United States
    • Sanger Heart and Vascular · Charlotte, United States
    • TriHealth Bethesda · Cincinnati, United States
    • University Hospitals Cleveland Medical Center · Cleveland, United States
    • Mercy Health- St. Vincent Medical Center LLC · Toledo, United States
    • UPMC Pinnacle Harrisburg · Harrisburg, United States
    • Lancaster General Hospital · Lancaster, United States
    • …and 10 more on the registry record
    Eligibility 2 inclusion criteria edited, 6 added, 1 removed; 3 exclusion criteria edited, 1 added, 1 removed
    What changed in the criteria
    Inclusion criteria
    • EditedLVEF ≥40 and ≤70% (as assessed by site echo). A historical echo within 60 days of consent may be used for baseline. Ultrafiltration should not be performed within 30 days of echo;
    • RemovedA. Heart failure hospitalization within 12 months prior to study consent OR an urgent heart failure visit requiring IV therapy within 6 months prior to study consent OR B. If there is no heart failure hospitalization within 12 months prior to study consent OR an urgent heart failure visit requiring IV therapy within 6 months prior to study consent, an elevated BMI-adjusted natriuretic peptide value must be achieved (Refer to Table 1 in Section 9.2.6)
    • AddedSubjects must meet at least one of the four following criteria:
    • AddedHeart failure admission (primary or secondary) within 12 months prior to study consent OR heart failure visit requiring IV therapy OR treated with outpatient Furoscix OR intensification of oral diuresis within 6 months prior to study consent II. PCWP > 15 mmHg up to 6 months prior to consent or within 30 days following consent III. IPAP reading of mean pressure ≥ 22 mmHg in 2 or more readings within 30 days of consent, or 3 or more readings within 60 days across different days, with a sensor implanted ≥ 3 months before first reading
    • AddedNatriuretic peptide value (NTproBNP or BNP) should meet or exceed the value below, depending on the presenting rhythm:
    • AddedNormal Sinus Rhythm (NSR): NTproBNP (pg/ml) ≥ 150 or BNP (pg/ml) ≥ 50
    • AddedAtrial Tachyarrhythmia (AT): NTproBNP (pg/ml) ≥ 450 or BNP (pg/ml) ≥ 150
    • AddedHistorical natriuretic peptide values within 6 months of consent may be used if subject is in NSR. Subjects in AT on baseline ECG must have natriuretic peptide values collected post-consent.
    • EditedHave stable, scheduled oral loop diuretic treatment (not just PRN) for a minimum of 30 days before providing study consent unless there is a documented allergy or intolerance. Spironolactone used as a diuretic for patients who cannot tolerate oral loop diuretic is an acceptable alternative.
    Exclusion criteria
    • ChangedBefore Exercise tolerance limited by a condition other than heart failure that, in the opinion of the investigator, contributes significantly to the primary symptoms of shortness of breath and/or exercise intolerance;Now Diagnosis of any of the following conditions that, in the opinion of the investigator, contributes significantly to the primary symptoms of exercise intolerance: angina, significant pulmonary disease, or currently requires 24-hour home oxygen use or scheduled oral steroids, peripheral vascular disease, orthopedic or rheumatologic conditions;
    • ChangedBefore Hypertrophic, infiltrative/restrictive or inflammatory cardiomyopathy;Now Infiltrative/restrictive (e.g., amyloidosis, sarcoidosis, hemochromatosis, Fabry, or radiation-induced heart disease), eccentric LV hypertrophy or inflammatory cardiomyopathy as documented in the medical record;
    • RemovedAcute, decompensated heart failure requiring IV therapy or ultrafiltration within 30 days prior to consent, in the hospital or an outpatient setting;
    • EditedUnable to follow through study protocol for any reasons (social support, incarceration, mental illness etc.) in the investigator's judgement.
    • AddedInsurance denial (after all attempts and appeals have been exhausted, and prior-authorization services utilized, if applicable)
    Site contacts Changed at 2 sites. See the sites
    Show 2 sites
    • St. Francis Hospital - Tulsa · Tulsa, United StatesContact •••8500→•••1606Contact m•••@saintfrancis.com→r•••@saintfrancis.com
    • Bon Secours St. Mary's · Richmond, United StatesContact person changed (no phone or email listed)
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

11

Registry details

Key details

Study ID
NCT05064709
Lead sponsor
Impulse Dynamics
Responsible party
Sponsor
First posted
Oct 1, 2021
Start date
Feb 3, 2022
Primary completion
Feb 1, 2029 (estimated)
Completion
Feb 1, 2029 (estimated)
Last update
Oct 23, 2026

Study contacts

Gary Cranke
Contact
aimhigher@impulsedynamics.com
(856) 642-9933
Javed Butler, MD, MPH, MBA
principal investigator · Baylor Scott and White Research Institute, Dallas, Texas
Oussama Wazni, MD, MBA
principal investigator · Department of Cardiovascular Medicine, Cleveland Clinic, Cleveland, Ohio, USA

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion